India, May 13 -- Bayer AG on Tuesday confirmed its currency-adjusted 2025 targets after reporting lower earnings in its first quarter with slightly lower sales. The quarterly results reflected weak results in the Crop Science Division, despite growth in Pharmaceuticals and Consumer Health segments.
For fiscal 2025, Bayer expects sales growth and the adjusted EBITDA margin at the Pharmaceuticals Division to come in at the upper end of the previous outlook range.
Shares of the Pharmaceutical and life sciences major were gaining around 6 percent on the XETRA in Germany, at 25.39 euros.
Regarding the new US tariffs, the company added that it is continuously evaluating the impacts of the current geopolitical developments, especially in relati...